American Therapeutics ANDA fraud
Executive Summary
FDA informs ATI in a March 26 letter that it is planning to withdraw approval of the company's danazol ANDA and in the meantime downgrade the product's rating in the "Orange Book" from "AB" to "BX." The agency said that it is initiating the action because of "untrue statements of material fact" found in a review of the ANDA. Earlier, FDA said that it has suspected ATI of falsifying its records for danazol to hide the use of an active ingredient from an unapproved source ("The Pink Sheet" Dec. 24, p. 5). ATI's danazol is the only approved generic version of Winthrop's Danocrine, an androgen used to treat endometriosis. The danazol ANDA was approved in December 1987. ATI was fined $ 1 mil. in October 1990 for making illegal payments to a former FDA review chemist during 1987 and falsifying documents for several other ANDAs....
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth